β-Adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density : Geelong Osteoporosis Study

Pasco, Julie A., Henry, Margaret J., Sanders, Kerrie M., Kotowicz, Mark A., Seeman, Ego and Nicholson, Geoffrey C. 2004, β-Adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density : Geelong Osteoporosis Study, Journal of bone and mineral research, vol. 19, no. 1, pp. 19-24.

Attached Files
Name Description MIMEType Size Downloads

Title β-Adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density : Geelong Osteoporosis Study
Alternative title Beta-Adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density : Geelong Osteoporosis Study
Author(s) Pasco, Julie A.
Henry, Margaret J.
Sanders, Kerrie M.
Kotowicz, Mark A.
Seeman, Ego
Nicholson, Geoffrey C.
Journal name Journal of bone and mineral research
Volume number 19
Issue number 1
Start page 19
End page 24
Total pages 6
Publisher Wiley - Blackwell
Place of publication Durham, NC
Publication date 2004-01
ISSN 0884-0431
1523-4681
Keyword(s) β-blocker
fracture
bone densitometry
population studies
case-control studies
Summary This population-based study documented β-blocker use in 59/569 cases with incident fracture and 112/775 controls. OR for fracture associated with β-blocker use was 0.68 (95%CI, 0.49–0.96). β-Blockers were associated with higher BMD at the total hip (2.5%) and UD forearm (3.6%) after adjusting for age, anthropometry, and thiazide use. β-Blocker use is associated with reduced fracture risk and higher BMD.

Introduction:
Animal data suggests that bone formation is under β-adrenergic control and that β-blockers stimulate bone formation and/or inhibit bone resorption.

Materials and Methods: We evaluated the association between β-blocker use, bone mineral density (BMD), and fracture risk in a population-based study in Geelong, a southeastern Australian city with a single teaching hospital and two radiological centers providing complete fracture ascertainment for the region. β-Blocker use was documented for 569 women with radiologically confirmed incident fractures and 775 controls without incident fracture. Medication use and lifestyle factors were documented by questionnaire.

Results:
Odds ratio for fracture associated with β-blocker use was 0.68 (95% CI, 0.49–0.96) for any fracture. Adjusting for age, weight, medications, and lifestyle factors had little effect on the odds ratio. β-Blocker use was associated with a higher BMD at the total hip (2.5%, p = 0.03) and ultradistal forearm (3.6%, p = 0.04) after adjustment for age, anthropometry, and thiazide use.

Conclusion:
β-Blockers are associated with a reduction in fracture risk and higher BMD.
Language eng
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2004, American Society for Bone and Mineral Research
Persistent URL http://hdl.handle.net/10536/DRO/DU:30042803

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 136 times in TR Web of Science
Google Scholar Search Google Scholar
Access Statistics: 45 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Thu, 01 Mar 2012, 10:34:42 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.